Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04551170 · ClinicalTrials.gov registry record · Phase 2

Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old

A Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, sponsored by Vanderbilt University Medical Center.

Active
Registry status
Phase 2
Development phase
34
Enrollment target
1
Study location

NCT04551170 is a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 34 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04551170, a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children.

Interventions

  • DRUG Placebo
  • DRUG Theophylline

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2020-07-13
Est. Completion 2026-12-31
Phase Phase 2

What the Registry Record Tells You About NCT04551170

The ClinicalTrials.gov registry entry for NCT04551170 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Albright Hereditary Osteodystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04551170 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04551170 about?

NCT04551170 is a clinical study titled "Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old". Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in...

What is the current status of trial NCT04551170?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-07-13. Estimated completion is 2026-12-31.

What conditions does trial NCT04551170 study?

This clinical trial studies the following conditions: Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1A.

What interventions are being tested in trial NCT04551170?

The interventions under investigation include: Placebo (DRUG), Theophylline (DRUG).

Who is sponsoring clinical trial NCT04551170?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04551170 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Albright Hereditary Osteodystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.